Clinical Trial Update: Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This update describes a Phase 2 clinical trial evaluating SX-682 in combination with enzalutamide for ARPI-resistant metastatic castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• SX-682
• Xtandi (enzalutamide)

Snippet

Sponsor: Syntrix Biosystems, Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING